⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4980824 | 0.96 | — | — | |
| SCHEMBL498933 | 0.96 | — | — | |
| SCHEMBL7280131 | 0.96 | ALDH1A1 (0.38) | — | |
| SCHEMBL128025 | 0.87 | — | — | |
| SCHEMBL126243 | 0.87 | — | — | |
| SCHEMBL17669593 | 0.70 | — | — | |
| SCHEMBL4523643 | 0.67 | — | — | |
| Ethylene SCHEMBL23698291 | 0.64 | ALDH1A1 (0.38) | — | |
| Ammonia Solution, Strong SCHEMBL27803488 | 0.64 | — | — | |
| SCHEMBL3588706 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230132298-A1 | OXABOROLE ESTERS AND USES THEREOF | ANACOR PHARMACEUTICALS, LLC | 2023-04-27 | — | — | US | claimed |
| US-11578087-B2 | Oxaborole esters and uses thereof | ANACOR PHARMACEUTICALS, INC. (US) | 2023-02-14 | — | — | US | claimed |
| US-20210101916-A1 | OXABOROLE ESTERS AND USES THEREOF | ANACOR PHARMACEUTICALS, INC. | 2021-04-08 | — | — | US | claimed |
| EP-3227263-B1 | CXCR7 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2019-04-10 | — | — | EP | claimed |
| US-10202368-B2 | CXCR7 receptor modulators | IDORSIA PHARMACEUTICALS LTD. (CH) | 2019-02-12 | — | — | US | claimed |
| US-9920010-B2 | CXCR7 receptor modulators | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-03-20 | — | — | US | claimed |
| US-20170327493-A1 | CXCR7 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2017-11-16 | — | — | US | claimed |
| EP-3227263-A1 | CXCR7 RECEPTOR MODULATORS | Actelion Pharmaceuticals Ltd (CH) | 2017-10-11 | — | — | EP | claimed |
| EP-3004082-B1 | CXCR7 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2017-08-02 | — | — | EP | claimed |
| WO-2016087370-A1 | CXCR7 RECEPTOR MODULATORS | ACTELION PHARMACEUTICALS LTD (CH) | 2016-06-09 | — | — | WO | claimed |
| WO-2007143526-A2 | SUBSTITUTED TETRAHYDROIMIDAZONAPHTHYRIDINES AND METHODS | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2007-12-13 | — | — | WO | claimed |
| EP-1851218-A2 | HYDROXYALKYL SUBSTITUTED IMIDAZOQUINOLINE COMPOUNDS AND METHODS | 3M Innovative Properties Company (US) | 2007-11-07 | — | — | EP | claimed |
| EP-1850849-A2 | METHOD OF PREFERENTIALLY INDUCING THE BIOSYNTHESIS OF INTERFERON | Coley Pharmaceutical Group, Inc. (US) | 2007-11-07 | — | — | EP | claimed |
| US-20070219228-A1 | Aryl substituted imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2007-09-20 | — | — | US | claimed |
| WO-2006091567-A2 | HYDROXYALKYL SUBSTITUTED IMIDAZOQUINOLINE COMPOUNDS AND METHODS | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2006-08-31 | — | — | WO | claimed |
| WO-2006091647-A2 | METHOD OF PREFERENTIALLY INDUCING THE BIOSYNTHESIS OF INTERFERON | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2006-08-31 | — | — | WO | claimed |
| WO-2006038923-A2 | ARYL SUBSTITUTED IMIDAZONAPHTHYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-04-13 | — | — | WO | claimed |
| EP-0028717-B1 | 6,7-BENZOMORPHAN DERIVATIVES, PROCESSES FOR THEIR PRODUCTION, PHARMACEUTICAL COMPOSITIONS CONTAINING SAID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | ACF CHEMIEFARMA NV (NL) | 1984-08-15 | — | — | EP | claimed |
| US-4425353-A | Analgesic 5-oxygenated-6,7-benzomorphan derivatives | ACF CHEMIEFARMA NV (NL) | 1984-01-10 | — | — | US | claimed |
| US-4406904-A | Method of inhibiting luteinizing hormone secretion with 6,7-benzomorphan derivatives | ACF CHEMIEFARMA NV (NL) | 1983-09-27 | — | — | US | claimed |